Pharmacokinetics of cannabinoids.

@article{Mcgilveray2005PharmacokineticsOC,
  title={Pharmacokinetics of cannabinoids.},
  author={I. Mcgilveray},
  journal={Pain research & management},
  year={2005},
  volume={10 Suppl A},
  pages={
          15A-22A
        }
}
  • I. Mcgilveray
  • Published 2005
  • Chemistry, Medicine
  • Pain research & management
Delta-9-tetrahydrocannabinol (Delta-9-THC) is the main psychoactive ingredient of cannabis (marijuana). The present review focuses on the pharmacokinetics of THC, but also includes known information for cannabinol and cannabidiol, as well as the synthetic marketed cannabinoids, dronabinol (synthetic THC) and nabilone. The variability of THC in plant material (0.3% to 30%) leads to variability in tissue THC levels from smoking, which is, in itself, a highly individual process. THC… Expand
113 Citations
Toxicological properties of Δ9-tetrahydrocannabinol and cannabidiol
  • K. Černe
  • Medicine
  • Arhiv za higijenu rada i toksikologiju
  • 2020
  • 3
  • PDF
The therapeutic use of cannabinoids: Forensic aspects.
  • 3
A cannabinoid analogue of Delta9-tetrahydrocannabinol disrupts neural development in chick.
  • 20
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 79 REFERENCES
Pharmacokinetics and Pharmacodynamics of Cannabinoids
  • 845
  • PDF
Bypassing the first-pass effect for the therapeutic use of cannabinoids
  • 59
Marijuana smoking: effect of varying delta 9-tetrahydrocannabinol content and number of puffs.
  • 113
Interactions in man of delta‐9‐tetrahydrocannabinol; II. Cannabinol and cannabidiol
  • 80
Tolerance and disposition of tetrahydrocannabinol in man.
  • C. A. Hunt, R. Jones
  • Chemistry, Medicine
  • The Journal of pharmacology and experimental therapeutics
  • 1980
  • 189
...
1
2
3
4
5
...